Russian Registry of Patients With nAMD

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

NCT04684394 ·Status: TERMINATED ·Phase: PHASE2

Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting

NCT05266495 ·Status: TERMINATED

Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)

NCT01024998 ·Status: COMPLETED ·Phase: PHASE1

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

NCT03930641 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD

NCT04331730 ·Status: COMPLETED ·Phase: PHASE2

Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.

NCT03714308 ·Status: COMPLETED

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

NCT01535950 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

NCT06196840 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Safety and Efficacy Study of LX102-C01 Treatment of Neovascular Age-Related Macular Degeneration (nAMD)

NCT05831007 ·Status: UNKNOWN ·Phase: NA

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

NCT05161806 ·Status: COMPLETED ·Phase: PHASE3

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

NCT05282004 ·Status: COMPLETED ·Phase: PHASE3

A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration

NCT03869684 ·Status: TERMINATED ·Phase: PHASE2

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

NCT03699618 ·Status: TERMINATED

A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration

NCT04594681 ·Status: TERMINATED ·Phase: PHASE1

NVAMD Satellite Study

NCT02251366 ·Status: COMPLETED ·Phase: NA

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

NCT02540954 ·Status: COMPLETED ·Phase: PHASE3

Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)

NCT05111743 ·Status: COMPLETED

Safety and Efficacy of AM712 in Patients with NAMD

NCT05345769 ·Status: COMPLETED ·Phase: PHASE1

A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment

NCT05473715 ·Status: TERMINATED ·Phase: PHASE4

Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD

NCT03386474 ·Status: COMPLETED ·Phase: PHASE3

Analysis of naïve Patients With Age-related Macular Degeneration of the Neovascular Type and Treated With Aflibercept (Eylea®) in "Treat-and-extend" at CHU Brugmann

NCT04891835 ·Status: COMPLETED

A Single-Center Pilot Study to Assess Macular Function

NCT01204541 ·Status: COMPLETED

Evaluation of Number of Patient Eyes That Remained on or Switched to Anti-VEGF Treatment After Initiation of Broluciumab

NCT05037396 ·Status: COMPLETED

Long-term Follow-up of Subfoveal Neovascular AMD

NCT01608113 ·Status: UNKNOWN

Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)

NCT01397409 ·Status: COMPLETED ·Phase: PHASE2